Falsified Medical Products in Francophone Sub-Saharan Africa

By HEOR Staff Writer

October 9, 2023

The Challenges of Substandard Medical Products

Substandard and falsified (SF) medical products pose a significant threat to public health. These products can cause harm, fuel resistance to genuine treatments, and undermine health systems. In Francophone sub-Saharan Africa, SF products are increasingly prevalent, largely due to the limited capacity of National Regulatory Authorities (NRAs) to fulfil their functions.

Solutions and Initiatives

Several initiatives are helping to combat this issue. The African Union (AU) and the World Health Organization (WHO) have launched the African Medicine Regulatory Harmonization (AMRH) Initiative and the African Medicines Agency (AMA). These initiatives aim to strengthen regulation and supply of quality-assured medical products.

The WHO Member State Mechanism is another important initiative, focusing on tackling SF medical products from a public health approach. Unfortunately, no NRAs in French-speaking Africa have yet achieved a maturity level 3. This indicates a stable, well-functioning, and integrated regulatory system. However, Burkina Faso, Niger, Ivory Coast, and Senegal are actively engaged in this process and could progress rapidly.

Academia also plays a crucial role in combating SF medical products. Universities like the University of Senegal Cheikh Anta Diop and the University of Douala in Cameroon have implemented a curriculum guide on SF medical products, educating future specialists and policymakers.

Procurement agencies, such as the Ecumenical Pharmaceutical Network (EPN), have also engaged in surveillance of SF medical products, integrating their data with national post-marketing surveillance of NRAs.

In conclusion, preventing, detecting, and responding to SF medical products remains a challenge in Francophone sub-Saharan Africa. However, through collective efforts and initiatives, progress is being made.

Reference url

Recent Posts

Paving the Way for Digital Health Technologies: NICE’s Bold New Strategy for the NHS

By HEOR Staff Writer

October 9, 2025

The National Institute for Health and Care Excellence (NICE) is expanding its technology appraisals programme, and starting April 2026, this will include digital health technologies that are placed on an equal legal footing with medicines in the NHS. This initiative forms part of the NHS 10-year ...
Health Misinformation Autism: The Dangers of Politicized Science in Vaccine and Drug Discourse

By João L. Carapinha

October 7, 2025

The BMJ article “Tylenol, vaccines, and autism: the medical mayhem of the MAGA methodologists” argues that political and ideological actors, notably aligned with the MAGA movement, are promoting health misinformation about autism, vaccines, and paracetamol. They amplify preliminary, misinterprete...
Pfizer Trump Drug Prices: A Landmark Deal for Affordable Medications

By Rene Pretorius

October 1, 2025

Summary President Trump announced that Pfizer has agreed to lower drug prices. This is part of a broader initiative to reduce prescription drug costs in the United States, particularly f...